Wednesday, January 26, 2022 3:40:57 PM
$OPGN
"We harness the power of molecular microbiology and bioinformatics to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and help improve antibiotic stewardship."
Headquartered in Rockville, Maryland, OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes.
Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR).
By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).
Recent OPGN News
- OpGen Provides Update on Business Operations and Strategic Opportunities • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shares Rip In Reaction To Activist Investor Becoming CEO • AllPennyStocks.com • 03/26/2024 08:20:00 PM
- OpGen Announces Acquisition of Preferred Stock by David Lazar • GlobeNewswire Inc. • 03/25/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:58:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:37:15 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/24/2023 05:15:18 AM
- OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:59:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:30:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:18:03 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/13/2023 09:17:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:15:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:14:21 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:13:12 PM
- OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds • GlobeNewswire Inc. • 10/12/2023 04:32:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:40:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:30:10 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 09/28/2023 08:24:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:30:09 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM